Core Viewpoint - The National Healthcare Security Administration (NHSA) has intensified its crackdown on bribery in the pharmaceutical sector, revealing multiple cases of corruption that highlight issues such as "kickbacks" and "golden sales" practices, which contribute to inflated drug prices and undermine fair market competition [3][4][6]. Summary by Sections Bribery Cases - In 2023, the NHSA disclosed eight bribery cases in the pharmaceutical field, involving not only hospital directors but also doctors and nurses [3][7]. - Specific cases include: - **Case of Tao**: Tao bribed a doctor with a total of 465,000 yuan (approximately 46.5 million) from 2016 to 2024 to promote a nasal spray product, resulting in a four-month detention and a fine of 10,000 yuan [6]. - **Case of Zhang**: Zhang was sentenced to one year in prison (with a six-month probation) and fined 20,000 yuan for bribing medical staff to promote a drug [6]. Regulatory Measures - The NHSA has established a credit evaluation system for pricing and procurement since 2020, aimed at addressing issues of bribery and ensuring compliance among pharmaceutical companies [9][10]. - The system categorizes companies into different levels of creditworthiness, with stricter penalties for those involved in bribery, including suspension of their products from procurement lists [10][11]. Ongoing Anti-Corruption Efforts - The trend of anti-corruption in the healthcare sector is shifting towards a more normalized governance approach, focusing on comprehensive oversight across the pharmaceutical supply chain [13]. - The NHSA's efforts are part of a broader initiative involving multiple government agencies to address issues related to healthcare fund management and to enhance regulatory measures [14].